Cardioprotective of Saffron (Crocus sativus L.) treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
10.1016/j.dcmed.2024.01.002
- Author:
Arlinda Silva Prameswari
1
,
2
,
3
;
Viskasari Pintoko Kalanjati
4
;
Tri Hartini Yuliawati
4
;
Abdurachman
4
;
Muhammad Miftahussurur
5
,
6
Author Information
1. Master Program of Basic Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java 60132, Indonesia
2. Department of Anatomy, Faculty of Medicine, Universitas Muhammadiyah Sidoarjo, Sidoarjo, East Java 61215, Indonesia
3. Department of Emergency Medicine, Pusura Candi Hospital, Sidoarjo, East Java 61271, Indonesia
4. Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java 60132, Indonesia
5. Helicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, East Java 60115, Indonesia
6. Departement of Internal Medicine, Faculty of Medicine, Dr. Soetomo General Academic Hospital, Universitas Airlangga, Surabaya, East Java 60285, Indonesia
- Publication Type:Meta-Analysis
- Keywords:
Saffron (Crocus sativus L.), Crocin Inflammatory cytokine, Meta-analysis, Systematic review, Type 2 diabetes mellitus (T2DM), Cardiovascular disease (CVD)
- From:
Digital Chinese Medicine
2023;6(4):381-392
- CountryChina
- Language:English
-
Abstract:
Objective:To investigate the cardioprotective effect of Saffron (Crocus sativus L.) treatment as
a potential supplement on patients with type 2 diabetes mellitus (T2DM).
Methods:Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were applied to analyze articles retrieved from PubMed, ScienceDirect, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), and China Biology Medicine (CBM) with a publication time span from January 15, 2015 to March 20, 2023. The articles were published in English only, including randomized controlled trials (RCTs) on adult patients who were diagnosed with T2DM, and received either Saffron or placebo treatment. Meta-analysis was performed using Review Manager 5.4 software. The present study was registered on the International Prospective Register of Systematic Reviews (PROSPERO) with a registration number as CRD42023443180.
Results:Seven RCTs with 455 patients were included in the study. The data revealed that Saffron treatment significantly reduced tumor necrosis factor (TNF)-α (P = 0.008) and fasting blood glucose (FBG) (P = 0.04) levels compared with what placebo did in T2DM patients. No significant differences were shown in the levels of interleukin (IL)-6, malondialdehyde (MDA), high serum C-reactive protein (hs-CRP), lipid profile, blood pressure, and body mass index (BMI) between Saffron and placebo ( P > 0.05) .
Conclusion:Saffron treatment has a cardioprotective effect in T2DM patients by reducing TNF-α and FBG levels. However, the potential anti-oxidant, anti-hypertensive, and anti-dyslipidaemia effects of the phytochemical need to be further investigated.
- Full text:Saffron.pdf
